Reviva Pharmaceuticals (RVPH) Holdings announced that it intends to offer shares of its common stock and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals Holdings: Positive Phase 3 Data and Favorable Safety Profile Support Buy Rating
- Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia
- Reviva Pharmaceuticals announces full dataset for one-year Phase 3 RECOVER study
- Reviva Pharmaceuticals Launches $50M At-Market Offering
- Reviva Pharmaceuticals Reports Q1 2025 Financial Results